Quest Diagnostics 2025-26: Revenue +12%, FY26 Adj EPS $10.50-$10.70
FY25 revenue $11.04B (+12%); op income $1.60B (+19%); NI $992M (+14%); EPS $8.75 (+14%). FCF $1.36B (+50%). Q4 revenue $2.81B (+7.1%); organic +6.4%. Diagnostic Information Services revenue +7.3% (physician + hospital + consumer + acquisitions). Total volume (requisitions) +8.5%; organic volume +7.9%. Revenue per requisition -0.1%. Excluding Corewell + Fresenius, organic volume +4.1% Q4, RPR +3%. Physician channel high single-digit organic Q4 (broad-based demand + geographic expansion). Hospital low single-digit (Collaborative Lab Solutions / CoLab). Consumer: questhealth.com expanded to 150+ tests + wellness partnerships. Clinical innovations: autoimmune testing, brain health (Alzheimer's), oncology (Haystack MRD, flow MRD). INFIGURATE program: 3% annual cost savings + AI/automation. PAMA legislation 1-year delay; RESULTS Act needed for structural fix. FY26 guide: revenue $11.7B-$11.82B (+6-7.1%); reported EPS $9.45-$9.65; adjusted EPS $10.50-$10.70; cash from operations ~$1.75B; capex ~$550M; ~$0.25 EPS dilution from Project Nova; CoLab with Corewell adding ~$250M organic revenue at low single-digit margins.
Key takeaways
-
FY25 revenue +12% to $11.04B; volume +8.5% Q4 — multi-driver organic + M&A acceleration. Quest's FY25 revenue jumped to $11.04B (+12% YoY from $9.87B FY24) — the highest growth rate in years. Q4 revenue +7.1% reported / +6.4% organic. Volume (requisitions) +8.5% Q4 with organic volume +7.9%. The volume growth is driven by (a) Corewell Health hospital lab acquisition contributing meaningfully, (b) Fresenius Medical Care acquisition contributing, (c) underlying organic +4.1% volume + +3% RPR (excluding the two acquisitions). The combination of M&A-driven step-up + healthy underlying organic growth is exactly the playbook management has been executing.
-
Hospital lab outsourcing — CoLab driving multi-year hospital channel growth. Quest's "Collaborative Lab Solutions" (CoLab) is a multi-year hospital outsourcing platform that helps hospital systems outsource their reference + esoteric + emergency lab work to Quest. FY25 saw the Corewell Health CoLab go-live and Fresenius Medical Care expansion. FY26 guide includes CoLab with Corewell adding ~$250M organic revenue at low single-digit margins. The CoLab model is structurally important because it locks in multi-year hospital relationships + creates volume scale advantages.
-
Consumer channel: questhealth.com 150+ tests + wellness partnerships — direct-to-consumer testing inflection. Quest is expanding its consumer-facing direct-to-consumer test menu via questhealth.com, now offering 150+ tests + partnerships with wellness companies. Direct-to-consumer testing is a multi-year growth pillar as: (a) consumers increasingly self-manage health via lab tests, (b) preventive + wellness testing TAM expanding, (c) Quest's brand + sample collection footprint creates structural advantage vs digital-only competitors.
-
Clinical innovation pipeline: Alzheimer's, oncology (Haystack MRD, flow MRD), autoimmune — multi-year revenue layer. Quest highlighted FY25 clinical innovations: brain health tests for Alzheimer's (the Eli Lilly + Eisai amyloid-targeting therapy environment is creating massive demand for plasma p-tau217 and amyloid PET surrogates), oncology Haystack MRD (minimal residual disease) + flow MRD, autoimmune testing. These are higher-acuity, higher-priced tests that boost RPR + margins. Multi-year compounding from clinical mix shift.
-
FY26 guide: revenue +6-7.1%; adj EPS $10.50-$10.70 — sustained mid-single-digit-plus EPS. From FY25 EPS $8.75 → FY26 adj EPS midpoint $10.60 = +21% growth (despite ~$0.25 Project Nova dilution + low-margin Corewell CoLab + weather impact in January 2026). Reported EPS $9.45-$9.65 reflects integration / amortization. Cash from operations ~$1.75B; capex ~$550M = ~$1.2B FCF. Multi-year capital return capacity.
Business
Quest Diagnostics Incorporated is the largest US clinical lab + diagnostic information services company, with multi-segment revenue:
- Diagnostic Information Services (~95%+ of revenue):
- Physician channel (~50%): Routine + esoteric clinical lab testing for office-based physicians. Q4 high single-digit organic growth.
- Hospital channel (~25%): Collaborative Lab Solutions (CoLab) outsourcing + reference / esoteric testing. Q4 low single-digit growth (Corewell + Fresenius onboarding).
- Consumer channel (~10-15%): Direct-to-consumer questhealth.com (150+ tests); employer + workplace; wellness partnerships.
- Other (~5-10%): Pharma services, drug abuse testing, PFAS / environmental, etc.
- Diagnostic Solutions (~5%): Lab products + diagnostics manufacturing.
Strategic moves FY25:
- Revenue +12% to $11.04B (highest growth rate in years)
- Corewell Health CoLab go-live
- Fresenius Medical Care lab expansion
- questhealth.com expanded to 150+ tests
- Wellness partnerships (consumer channel)
- Clinical innovations: Alzheimer's brain health, oncology (Haystack MRD, flow MRD), autoimmune
- INFIGURATE program: 3% annual cost savings + AI/automation
- Geographic expansion (physician channel)
- PAMA legislation: one-year delay (regulatory tailwind)
- $450M FY25 buyback (+198% YoY)
- Multi-year M&A pipeline
FY25 financial performance
| Metric (FY) | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue ($B) | 9.88 | 9.25 | 9.87 | 11.04 |
| Revenue YoY | n/a | -6% | +7% | +12% |
| Op income ($B) | 1.43 | 1.26 | 1.35 | 1.60 |
| Op margin | 14.4% | 13.6% | 13.6% | 14.5% |
| Net income ($M) | 946 | 854 | 871 | 992 |
| Diluted EPS ($) | 7.98 | 7.52 | 7.69 | 8.75 |
| FCF ($M) | 1,314 | 864 | 909 | 1,359 |
| Capex ($M) | -404 | -408 | -425 | -527 |
| Total debt ($B) | 4.71 | 5.50 | 7.09 | 6.92 |
| Buyback ($M) | -1,408 | -275 | -151 | -450 |
| Dividends ($M) | -305 | -314 | -331 | -353 |
Note: FY22 reflects post-COVID baseline. FY23 was the trough as COVID testing revenue normalized. FY24-25 reflects multi-year M&A integration + organic recovery.
The earnings progression: revenue trajectory accelerated from -6% (FY23) → +7% (FY24) → +12% (FY25). Op margin expanded modestly to 14.5% (FY25, up from 13.6% FY24) reflecting INFIGURATE 3% productivity + scale.
FCF $1.36B FY25 (+50%) — cash generation acceleration. Total debt $6.92B (-2%) — modest deleveraging post-acquisitions. Buyback $450M FY25 (+198% YoY) reflects management confidence.
Capital allocation
- Capex: $-527M FY25 (+24% YoY); FY26 guide ~$550M.
- Dividends: $-353M FY25 (+7% YoY) — progressive dividend.
- Buybacks: $-450M FY25 (+198% YoY).
- Total capital return FY25: ~$803M.
- Total debt: $6.92B (-2% YoY).
- FCF: $1.36B FY25 (+50% YoY).
- FY26 cash from operations: ~$1.75B.
FY26 outlook (per Q4 2025 call, 2026-02-10)
| FY26 framework | Detail |
|---|---|
| Revenue | $11.7B to $11.82B (+6.0% to +7.1%) |
| Reported EPS | $9.45 to $9.65 |
| Adjusted EPS | $10.50 to $10.70 |
| Cash from operations | ~$1.75B |
| Capex | ~$550M |
| FCF (implied) | ~$1.2B |
| Project Nova EPS dilution | ~$0.25 |
| Weather impact January 2026 | Considered |
| No PAMA impact in 2026 | Confirmed |
| CoLab with Corewell | ~$250M organic revenue at low single-digit margins |
Management noted continued multi-channel growth + M&A integration + INFIGURATE productivity + AI/automation + clinical innovation pipeline.
Key risks
PAMA / Medicare reimbursement. Protecting Access to Medicare Act (PAMA) creates multi-year reimbursement pressure on clinical lab tests. The one-year delay in 2025-2026 is a tailwind but RESULTS Act needed for structural fix. Long-term reimbursement environment uncertain.
Hospital outsourcing competitive landscape. LabCorp + regional hospital systems compete in hospital lab outsourcing. CoLab platform vs LabCorp's hospital relationships matters.
M&A integration risk. Corewell Health + Fresenius + other acquisitions require multi-year integration. Margin compression near-term (low single-digit margins on Corewell CoLab) is expected but execution matters.
Project Nova execution. ~$0.25 EPS dilution in 2026 from Project Nova (multi-year strategic platform investment). Execution + benefit realization timing matters.
Consumer channel competition. Direct-to-consumer testing competitive landscape (Function Health, Hims, Lemonade, others) growing. Quest's brand + sample collection moat needs to compound.
Reimbursement complexity. Medicare + Medicaid + commercial insurer + employer + uninsured all different rate environments. Multi-year reimbursement complexity.
Clinical innovation execution. Alzheimer's brain health, oncology MRD, autoimmune testing growth depends on lab capacity + commercial team + reimbursement. Multi-year ramp.
INFIGURATE productivity. 3% annual cost savings target requires continuous execution. Any slowdown affects margin trajectory.
Volume mix / RPR dynamics. Revenue per requisition trends matter alongside volume. Mix shift toward routine tests can pressure RPR; toward esoteric / clinical innovation supports RPR.
FX (limited). Most US-domestic; limited FX exposure.
Cybersecurity + patient data. Multi-region patient data + payment processing creates cybersecurity attack surface.
Regulatory landscape. FDA + CLIA + state-level laboratory regulations.
Talent retention. Lab technicians, pathologists, technical staff multi-year competitive market.
Pharma + life sciences services dynamics. Pharma trial volumes + life sciences services revenue cyclicality.
Bottom line
Quest Diagnostics FY25 is the multi-channel growth + M&A integration + clinical innovation acceleration year: revenue $11.04B (+12%); op income $1.60B (+19%); NI $992M (+14%); EPS $8.75 (+14%). FCF $1.36B (+50%). Q4 revenue $2.81B (+7.1%); organic +6.4%; volume +8.5%; organic volume +7.9%. Physician channel high single-digit organic growth; Hospital low single-digit (CoLab); Consumer questhealth.com expanded to 150+ tests + wellness partnerships. Clinical innovations: Alzheimer's brain health, oncology (Haystack MRD, flow MRD), autoimmune. INFIGURATE program: 3% annual cost savings + AI/automation. PAMA 1-year delay. Buyback $450M (+198%); dividend $353M (+7%); total capital return $803M.
FY26 guide: revenue $11.7-$11.82B (+6-7.1%); reported EPS $9.45-$9.65; adjusted EPS $10.50-$10.70; cash from operations ~$1.75B; capex ~$550M; ~$0.25 Project Nova EPS dilution; no PAMA impact 2026; CoLab with Corewell adding ~$250M organic revenue at low single-digit margins.
The risks are real — PAMA / Medicare reimbursement, hospital outsourcing competitive landscape (LabCorp + regional hospitals), M&A integration risk, Project Nova execution, consumer channel competition (Function Health, Hims, Lemonade, others), reimbursement complexity, clinical innovation execution, INFIGURATE productivity discipline, volume mix / RPR dynamics, cybersecurity + patient data, regulatory landscape (FDA + CLIA + state), talent retention, pharma + life sciences services cyclicality.
But the structural thesis (largest US clinical lab + diagnostic information services + ~$11B revenue + 4-channel platform (physician + hospital + consumer + diagnostic solutions) + Corewell Health CoLab live + Fresenius Medical Care expansion + questhealth.com 150+ tests + wellness partnerships + Alzheimer's brain health + oncology Haystack MRD + flow MRD + autoimmune testing + INFIGURATE 3% annual productivity + AI/automation + multi-year M&A pipeline + PAMA delay + adj EPS $10.50-$10.70 FY26 guide + ~$1.75B FY26 cash from operations + buyback +198%) is intact and FY25 confirms.
Quality US clinical lab + diagnostic services compounder mid-cycle, with multi-channel platform + clinical innovation pipeline + hospital outsourcing momentum + consumer channel inflection + INFIGURATE productivity + AI integration + multi-year M&A. The FY25 +12% revenue + +14% EPS + Q4 volume +8.5% + clinical innovation pipeline + INFIGURATE 3% + Corewell + Fresenius + questhealth.com 150+ tests + FY26 +6-7.1% revenue + adj EPS $10.50-$10.70 + buyback +198% + multi-year capital return creates one of the cleaner US clinical lab compounding setups for investors seeking exposure to clinical lab demand + multi-channel growth + clinical innovation + M&A + hospital outsourcing + consumer testing inflection. The conservative FY26 framework + multi-year M&A pipeline + clinical innovation + INFIGURATE + PAMA delay + multi-year capital return provides multiple paths to outperformance over a multi-year horizon. PAMA / reimbursement + competitive landscape + M&A integration + Project Nova execution remain ongoing risks, but the multi-channel diversification + clinical innovation + cost discipline + scale support continued compounding through cycles.
Citations
- Quest Diagnostics Incorporated FY25 Form 10-K (filed February 2026, SEC EDGAR).
- DGX Q4 2025 earnings call, 2026-02-10 — Q4 revenue $2.81B (+7.1%); organic +6.4%; DIS +7.3%; volume +8.5% (organic +7.9%); RPR -0.1%; ex-Corewell + Fresenius organic volume +4.1%, RPR +3%; physician channel high single-digit organic; hospital channel low single-digit (CoLab driving); consumer questhealth.com 150+ tests + wellness partnerships; clinical innovations: autoimmune, brain health Alzheimer's, oncology Haystack MRD + flow MRD; INFIGURATE 3% annual cost savings + AI/automation; PAMA 1-year delay (RESULTS Act needed); FY26 revenue $11.7B-$11.82B (+6-7.1%); reported EPS $9.45-$9.65; adjusted EPS $10.50-$10.70; cash from operations ~$1.75B; capex ~$550M; ~$0.25 EPS dilution from Project Nova; weather impact January 2026; no PAMA impact 2026; CoLab with Corewell adding ~$250M organic revenue at low single-digit margins.
- DGX Q3 / Q2 / Q1 2025 earnings calls — supporting volume + organic + M&A integration + clinical innovation progression.
- Internal financial_statements view (consolidated annual + cash flow + capital structure).